Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 7/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896888 | 0.90 | MEN1 (0.42) | MAPTLMNAGAANPSR1ALDH1A1 | |
| SCHEMBL18318149 | 0.75 | L3MBTL1 (0.42) | MAPTHTTUSP2POLBKMT2A | |
| SCHEMBL16896877 | 0.73 | TSHR (0.47) | MAPTLMNAHTTGAAALDH1A1 | |
| SCHEMBL16896942 | 0.72 | L3MBTL1 (0.44) | HTTUSP2SLC5A1SLC5A2PIK3CG | |
| SCHEMBL6831724 | 0.67 | ALDH1A1 (0.68) | MAPTLMNAHTTUSP2GAA | |
| SCHEMBL16905853 | 0.65 | CPT1A (0.42) | MAPTHTTUSP2NPSR1POLB | |
| SCHEMBL3716566 | 0.65 | PIK3CD (0.64) | PIK3CG | |
| SCHEMBL16896805 | 0.65 | BRD4 (0.38) | HTTUSP2ALDH1A1POLBPIK3CG | |
| SCHEMBL16896882 | 0.65 | PIK3CG (0.42) | MAPTHTTUSP2POLBSLC5A1 | |
| SCHEMBL16905841 | 0.65 | L3MBTL1 (0.53) | HTTUSP2KMT2AMEN1SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | MAPT 2737/4885LMNA 823/4885HTT 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.